Agios Pharmaceuticals, Inc. Share Price Today: Live Updates & Key Insights

Agios Pharmaceuticals, Inc. share price today is $27.31, up -0.21%. The stock opened at $27.81 against the previous close of $27.92, with an intraday high of $28.28 and low of $27.49.

Agios Pharmaceuticals, Inc. Share Price Chart

Agios Pharmaceuticals, Inc.

us-stock
To Invest in {{usstockname}}
us-stock

Agios Pharmaceuticals, Inc. Share Price Performance

$27.31 -0.0021(-0.21%) AGIO at 23 Mar 2026 11:55 AM Biotechnology
Lowest Today 27.49
Highest Today 28.28
Today’s Open 27.81
Prev. Close 27.92
52 Week High 46.00
52 Week Low 22.24
Day’s Range: Low 27.49 High 28.28
52-Week Range: Low 22.24 High 46.00
1 day return -
1 Week return -3.43
1 month return -7.71
3 month return +11.56
6 month return -27.0
1 year return -13.76
3 year return +27.6
5 year return -47.21
10 year return -

Agios Pharmaceuticals, Inc. Institutional Holdings

Vanguard Group Inc 9.55

Farallon Capital Management, L.L.C. 8.81

BlackRock Inc 7.76

BB Biotech AG Ord 6.34

Armistice Capital, LLC 5.18

Erste Asset Management GmbH 4.79

State Street Corp 3.86

Macquarie Group Ltd 3.34

Vanguard Total Stock Mkt Idx Inv 3.16

D. E. Shaw & Co LP 3.14

State Street® SPDR® S&P® Biotech ETF 3.07

T. Rowe Price Associates, Inc. 2.83

TCG Crossover Management, LLC 2.44

Geode Capital Management, LLC 2.41

iShares Russell 2000 ETF 2.34

Citadel Advisors Llc 2.30

Vanguard Small Cap Index 2.25

Frazier Life Sciences Management, L.P. 2.18

Nomura Small Cap Core I 2.13

GW&K Investment Management, LLC 2.06

Susquehanna International Group, LLP 1.95

Bank of America Corp 1.93

Jane Street Group LLC 1.91

Dimensional Fund Advisors, Inc. 1.71

BNP Paribas Investment Partners SA 1.69

Deutsche Bank AG 1.58

Vanguard Small Cap Growth Index Inv 1.25

BNP Paribas US Small Cap ClassicC 1.25

American Funds SMALLCAP World A 1.20

Vanguard Institutional Extnd Mkt Idx Tr 1.08

BNP Paribas Health Cr Innovtr Cl Cap 0.98

Fidelity Small Cap Index 0.94

iShares Russell 2000 Value ETF 0.83

Strategic Advisers U.S. Total Stock 0.72

iShares Biotechnology ETF 0.70

BlackRock Health Sciences Opps Inv A 0.59

State St Russell Sm/Mid Cp® Indx SL Cl I 0.55

Fidelity Extended Market Index 0.55

T. Rowe Price Health Sciences 0.54

Artisan International Small-Mid Investor 0.53

Agios Pharmaceuticals, Inc. Market Status

Strong Buy: 3

Buy: 3

Hold: 3

Sell: 0

Strong Sell: 0

Agios Pharmaceuticals, Inc. Fundamentals

Market Cap 1632.38 M

PB Ratio 1.3691

PE Ratio 0.0

Enterprise Value 819.33 M

Total Assets 1297.23 M

Volume 1618703

Agios Pharmaceuticals, Inc. Company Financials

Annual Revenue FY25:54028000 54.0M, FY24:36498000 36.5M, FY23:24030000 24.0M, FY22:14240000 14.2M, FY21:41409 0.0M

Annual Profit FY25:47683000 47.7M, FY24:32333000 32.3M, FY23:21322000 21.3M, FY22:12536000 12.5M, FY21:40703 0.0M

Annual Net worth FY25:-412781000 -412.8M, FY24:673725000 673.7M, FY23:-219622000 -219.6M, FY22:-74555000 -74.6M, FY21:1604715000 1604.7M

Quarterly Revenue Q4/2025:19967000 20.0M, Q3/2025:12880000 12.9M, Q2/2025:12455000 12.5M, Q1/2025:8726000 8.7M, Q4/2024:10730000 10.7M

Quarterly Profit Q4/2025:19347000 19.3M, Q3/2025:11201000 11.2M, Q2/2025:9494000 9.5M, Q1/2025:7641000 7.6M, Q4/2024:9470000 9.5M

Quarterly Net worth Q4/2025:-108039000 -108.0M, Q3/2025:-103433000 -103.4M, Q2/2025:-112020000 -112.0M, Q1/2025:-89289000 -89.3M, Q4/2024:-96523000 -96.5M

About Agios Pharmaceuticals, Inc. & investment objective

Company Information Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 539

Industry Biotechnology

CEO Mr. Brian M. Goff M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Agios Pharmaceuticals, Inc. FAQs

What is the share price of Agios Pharmaceuticals, Inc. today?

The current share price of Agios Pharmaceuticals, Inc. is $27.31.

Can I buy Agios Pharmaceuticals, Inc. shares in India?

Yes, Indian investors can buy Agios Pharmaceuticals, Inc. shares by opening an international trading and demat account with Motilal Oswal.

How to buy Agios Pharmaceuticals, Inc. shares in India?

You can easily invest in Agios Pharmaceuticals, Inc. shares from India by:

Can I buy fractional shares of Agios Pharmaceuticals, Inc.?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Agios Pharmaceuticals, Inc.?

Agios Pharmaceuticals, Inc. has a market cap of $1632.38 M.

In which sector does Agios Pharmaceuticals, Inc. belong?

Agios Pharmaceuticals, Inc. operates in the Biotechnology sector.

What documents are required to invest in Agios Pharmaceuticals, Inc. stocks?

To invest, you typically need:

What is the PE and PB ratio of Agios Pharmaceuticals, Inc.?

The PE ratio of Agios Pharmaceuticals, Inc. is N/A and the PB ratio is 1.37.